For your patients with ADHD who are 6 years and older
QuilliChew ER® delivers
Patients' response to medications can vary.
With QuilliChew ER® tablets, drug release is not affected by methylphenidate metabolism, food timing or type, location of release in the GI tract, or pH of the GI tract.2
Unique technology provides continuous release of methylphenidate1
• Predictable symptom control from patient to patient1,3
Effective symptom control through
the most important parts of the day 3
Consistent PK profile with no
additional peak or crash2
Most dosing options in an
ER methylphenidate tablet
ADHD, Attention Deficit Hyperactivity Disorder; ER, extended-release; IR, immediate-release; PK, pharmacokinetic.
References: 1. Kando JC, King TR, Pardo A. A novel, modified-release drug delivery technology containing amphetamine and methylphenidate ion-exchange complexes. Poster presented at: American Psychiatric Association Annual Meeting; May 1-3, 2021. 2. Herman BK, King TR, Kando JC, Pardo A. Poster presented at: Neuroscience Education Institute Congress; November 7-11, 2018; Orlando, FL. 3. Wigal SB, Childress A, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(8):690-699.